100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43AI148018
Award Date
4/20/20
Completion Date
9/30/21
Dollars Obligated
$289K
Overview
Activity
9
Transactions
9
Subawards
Similar Awards
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Fina Biosolutions LLC (DV4LJ9BSNXH7)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Update #1
Update #2
GENETICALLY DETOXIFIED TETANUS TOXIN FOR USE IN VACCINES
Posted 4/20/20
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
GENETICALLY DETOXIFIED TETANUS TOXIN FOR USE IN VACCINES - SUMMARY TETANUS AND DIPHTHERIA TOXOIDS ARE HIGHLY EFFECTIVE VACCINES FOR PREVENTING DISEASES. AS "CARRIER PROTEINS", TETANUS AND DIPHTHERIA TOXOIDS ENHANCE THE IMMUNOGENICITY OF SMALL MOLECULES AND POLYSACCHARIDES. HOWEVER, TETANUS TOXOID (TTXD) REPRESENTS ONLY 20-70% OF THE PROTEIN IN THE TTXD VACCINE AND THE TTXD VACCINE CONTAINS HUNDREDS OF 'UN-INTENDED/CONTAMINANT' CLOSTRIDIAL PROTEINS. PURIFICATION IS OFTEN NEEDED PRIOR TO TTXD USE A CONJUGATE VACCINE CARRIER. TT IS DETOXIFIED WITH FORMALDEHYDE, USING AN OVER 30-DAY INCUBATION THAT BLOCKS A SUBSET LYSINES THAT CANNOT THEN BE USED FOR CONJUGATION WITH ANTIGENS. COLLABORATORS AT THE MEDICAL COLLEGE OF WISCONSIN HAVE ENGINEERED A FULL-LENGTH, ATOXIC TETANUS TOXIN (M8TT) WITH 8 INDEPENDENT MUTATIONS REDUCING CATALYSIS, TRANSLOCATION, AND BINDING FUNCTIONS. HERE, FINA BIOSOLUTIONS (FINABIO) PROPOSES TO DEVELOP AND MANUFACTURE M8TT IN A PROPRIETARY ENGINEERED E. COLI STRAIN THAT HAS A UNIQUE OXIDATIVE ENVIRONMENT. THIS STRAIN HAS BEEN USED SUCCESSFULLY TO PRODUCE MULTI-GRAMS/L AMOUNTS OF CRM197, A MUTATED FORM OF DIPHTHERIA TOXIN THAT HAS BEEN SUCCESSFULLY USED AS A RECOMBINANTLY EXPRESSED VACCINE PROTEIN CARRIER. THIS PROPOSAL USES RECOMBINANT DNA TECHNOLOGY, BIOTECHNOLOGY, BIOCHEMISTRY AND IMMUNOLOGICAL APPROACHES TO PRODUCE AND TEST THE IMMUNOLOGICAL POTENCY OF THIS NEXT GENERATION CONJUGATE TETANUS VACCINE PLATFORM. THE SPECIFIC AIMS FOR PHASE I ARE TO: SUBCLONE AND SCALE UP PRODUCTION AND PURIFY > 1 G/L OF M8TT AT >95% PURITY; AND TO TEST THE IMMUNOLOGICAL PROPERTIES OF M8TT VERSUS CONVENTIONAL TTXD TO PRODUCE A CONJUGATE OF HEMOPHILUS INFLUENZAE SUBTYPE B POLYRIBITOL PHOSPHATE SUGAR PRP CONJUGATED TO M8TT AND TTXD TO DETERMINE IF PRP-TTXD IS A MORE POTENT CONJUGATE VACCINE TO PRP AND TT THAN PRP-TTXD. IF SUCCESSFUL, PHASE II STUDIES WILL OPTIMIZE THE M8TT MANUFACTURING PROCESS TO 50 L PRODUCTION SCALE AND CHARACTERIZE THE PRODUCT FOR SAFETY AND EFFICACY IN PRE-CLINICAL TRIALS. IN ADDITION, THE UTILITY OF M8TT AS A VACCINE CARRIER PROTEIN WILL BE FURTHER EXPLORED WITH ADDITIONAL ANTIGENS, INCLUDING SMALL MOLECULES AND OTHER POLYSACCHARIDES. ULTIMATELY, A SUPERIOR TETANUS VACCINE PROTEIN WILL BE COMMERCIALIZED BY ADVANCING A 50-YEAR OLD INDUSTRIAL TECHNOLOGY WITH A NEW, MODERNIZED, ECONOMIC, EFFECTIVE, AND SAFE CONJUGATE TT VACCINE PLATFORM.
$0
1/27/23
Not listed
GENETICALLY DETOXIFIED TETANUS TOXIN FOR USE IN VACCINES - SUMMARY TETANUS AND DIPHTHERIA TOXOIDS ARE HIGHLY EFFECTIVE VACCINES FOR PREVENTING DISEASES. AS "CARRIER PROTEINS", TETANUS AND DIPHTHERIA TOXOIDS ENHANCE THE IMMUNOGENICITY OF SMALL MOLECULES AND POLYSACCHARIDES. HOWEVER, TETANUS TOXOID (TTXD) REPRESENTS ONLY 20-70% OF THE PROTEIN IN THE TTXD VACCINE AND THE TTXD VACCINE CONTAINS HUNDREDS OF 'UN-INTENDED/CONTAMINANT' CLOSTRIDIAL PROTEINS. PURIFICATION IS OFTEN NEEDED PRIOR TO TTXD USE A CONJUGATE VACCINE CARRIER. TT IS DETOXIFIED WITH FORMALDEHYDE, USING AN OVER 30-DAY INCUBATION THAT BLOCKS A SUBSET LYSINES THAT CANNOT THEN BE USED FOR CONJUGATION WITH ANTIGENS. COLLABORATORS AT THE MEDICAL COLLEGE OF WISCONSIN HAVE ENGINEERED A FULL-LENGTH, ATOXIC TETANUS TOXIN (M8TT) WITH 8 INDEPENDENT MUTATIONS REDUCING CATALYSIS, TRANSLOCATION, AND BINDING FUNCTIONS. HERE, FINA BIOSOLUTIONS (FINABIO) PROPOSES TO DEVELOP AND MANUFACTURE M8TT IN A PROPRIETARY ENGINEERED E. COLI STRAIN THAT HAS A UNIQUE OXIDATIVE ENVIRONMENT. THIS STRAIN HAS BEEN USED SUCCESSFULLY TO PRODUCE MULTI-GRAMS/L AMOUNTS OF CRM197, A MUTATED FORM OF DIPHTHERIA TOXIN THAT HAS BEEN SUCCESSFULLY USED AS A RECOMBINANTLY EXPRESSED VACCINE PROTEIN CARRIER. THIS PROPOSAL USES RECOMBINANT DNA TECHNOLOGY, BIOTECHNOLOGY, BIOCHEMISTRY AND IMMUNOLOGICAL APPROACHES TO PRODUCE AND TEST THE IMMUNOLOGICAL POTENCY OF THIS NEXT GENERATION CONJUGATE TETANUS VACCINE PLATFORM. THE SPECIFIC AIMS FOR PHASE I ARE TO: SUBCLONE AND SCALE UP PRODUCTION AND PURIFY > 1 G/L OF M8TT AT >95% PURITY; AND TO TEST THE IMMUNOLOGICAL PROPERTIES OF M8TT VERSUS CONVENTIONAL TTXD TO PRODUCE A CONJUGATE OF HEMOPHILUS INFLUENZAE SUBTYPE B POLYRIBITOL PHOSPHATE SUGAR PRP CONJUGATED TO M8TT AND TTXD TO DETERMINE IF PRP-TTXD IS A MORE POTENT CONJUGATE VACCINE TO PRP AND TT THAN PRP-TTXD. IF SUCCESSFUL, PHASE II STUDIES WILL OPTIMIZE THE M8TT MANUFACTURING PROCESS TO 50 L PRODUCTION SCALE AND CHARACTERIZE THE PRODUCT FOR SAFETY AND EFFICACY IN PRE-CLINICAL TRIALS. IN ADDITION, THE UTILITY OF M8TT AS A VACCINE CARRIER PROTEIN WILL BE FURTHER EXPLORED WITH ADDITIONAL ANTIGENS, INCLUDING SMALL MOLECULES AND OTHER POLYSACCHARIDES. ULTIMATELY, A SUPERIOR TETANUS VACCINE PROTEIN WILL BE COMMERCIALIZED BY ADVANCING A 50-YEAR OLD INDUSTRIAL TECHNOLOGY WITH A NEW, MODERNIZED, ECONOMIC, EFFECTIVE, AND SAFE CONJUGATE TT VACCINE PLATFORM.
$0
1/27/23
Not listed
GENETICALLY DETOXIFIED TETANUS TOXIN FOR USE IN VACCINES - SUMMARY TETANUS AND DIPHTHERIA TOXOIDS ARE HIGHLY EFFECTIVE VACCINES FOR PREVENTING DISEASES. AS "CARRIER PROTEINS", TETANUS AND DIPHTHERIA TOXOIDS ENHANCE THE IMMUNOGENICITY OF SMALL MOLECULES AND POLYSACCHARIDES. HOWEVER, TETANUS TOXOID (TTXD) REPRESENTS ONLY 20-70% OF THE PROTEIN IN THE TTXD VACCINE AND THE TTXD VACCINE CONTAINS HUNDREDS OF 'UN-INTENDED/CONTAMINANT' CLOSTRIDIAL PROTEINS. PURIFICATION IS OFTEN NEEDED PRIOR TO TTXD USE A CONJUGATE VACCINE CARRIER. TT IS DETOXIFIED WITH FORMALDEHYDE, USING AN OVER 30-DAY INCUBATION THAT BLOCKS A SUBSET LYSINES THAT CANNOT THEN BE USED FOR CONJUGATION WITH ANTIGENS. COLLABORATORS AT THE MEDICAL COLLEGE OF WISCONSIN HAVE ENGINEERED A FULL-LENGTH, ATOXIC TETANUS TOXIN (M8TT) WITH 8 INDEPENDENT MUTATIONS REDUCING CATALYSIS, TRANSLOCATION, AND BINDING FUNCTIONS. HERE, FINA BIOSOLUTIONS (FINABIO) PROPOSES TO DEVELOP AND MANUFACTURE M8TT IN A PROPRIETARY ENGINEERED E. COLI STRAIN THAT HAS A UNIQUE OXIDATIVE ENVIRONMENT. THIS STRAIN HAS BEEN USED SUCCESSFULLY TO PRODUCE MULTI-GRAMS/L AMOUNTS OF CRM197, A MUTATED FORM OF DIPHTHERIA TOXIN THAT HAS BEEN SUCCESSFULLY USED AS A RECOMBINANTLY EXPRESSED VACCINE PROTEIN CARRIER. THIS PROPOSAL USES RECOMBINANT DNA TECHNOLOGY, BIOTECHNOLOGY, BIOCHEMISTRY AND IMMUNOLOGICAL APPROACHES TO PRODUCE AND TEST THE IMMUNOLOGICAL POTENCY OF THIS NEXT GENERATION CONJUGATE TETANUS VACCINE PLATFORM. THE SPECIFIC AIMS FOR PHASE I ARE TO: SUBCLONE AND SCALE UP PRODUCTION AND PURIFY > 1 G/L OF M8TT AT >95% PURITY; AND TO TEST THE IMMUNOLOGICAL PROPERTIES OF M8TT VERSUS CONVENTIONAL TTXD TO PRODUCE A CONJUGATE OF HEMOPHILUS INFLUENZAE SUBTYPE B POLYRIBITOL PHOSPHATE SUGAR PRP CONJUGATED TO M8TT AND TTXD TO DETERMINE IF PRP-TTXD IS A MORE POTENT CONJUGATE VACCINE TO PRP AND TT THAN PRP-TTXD. IF SUCCESSFUL, PHASE II STUDIES WILL OPTIMIZE THE M8TT MANUFACTURING PROCESS TO 50 L PRODUCTION SCALE AND CHARACTERIZE THE PRODUCT FOR SAFETY AND EFFICACY IN PRE-CLINICAL TRIALS. IN ADDITION, THE UTILITY OF M8TT AS A VACCINE CARRIER PROTEIN WILL BE FURTHER EXPLORED WITH ADDITIONAL ANTIGENS, INCLUDING SMALL MOLECULES AND OTHER POLYSACCHARIDES. ULTIMATELY, A SUPERIOR TETANUS VACCINE PROTEIN WILL BE COMMERCIALIZED BY ADVANCING A 50-YEAR OLD INDUSTRIAL TECHNOLOGY WITH A NEW, MODERNIZED, ECONOMIC, EFFECTIVE, AND SAFE CONJUGATE TT VACCINE PLATFORM.
$289.1k
1/11/22
Not listed
GENETICALLY DETOXIFIED TETANUS TOXIN FOR USE IN VACCINES - SUMMARY TETANUS AND DIPHTHERIA TOXOIDS ARE HIGHLY EFFECTIVE VACCINES FOR PREVENTING DISEASES. AS "CARRIER PROTEINS", TETANUS AND DIPHTHERIA TOXOIDS ENHANCE THE IMMUNOGENICITY OF SMALL MOLECULES AND POLYSACCHARIDES. HOWEVER, TETANUS TOXOID (TTXD) REPRESENTS ONLY 20-70% OF THE PROTEIN IN THE TTXD VACCINE AND THE TTXD VACCINE CONTAINS HUNDREDS OF 'UN-INTENDED/CONTAMINANT' CLOSTRIDIAL PROTEINS. PURIFICATION IS OFTEN NEEDED PRIOR TO TTXD USE A CONJUGATE VACCINE CARRIER. TT IS DETOXIFIED WITH FORMALDEHYDE, USING AN OVER 30-DAY INCUBATION THAT BLOCKS A SUBSET LYSINES THAT CANNOT THEN BE USED FOR CONJUGATION WITH ANTIGENS. COLLABORATORS AT THE MEDICAL COLLEGE OF WISCONSIN HAVE ENGINEERED A FULL-LENGTH, ATOXIC TETANUS TOXIN (M8TT) WITH 8 INDEPENDENT MUTATIONS REDUCING CATALYSIS, TRANSLOCATION, AND BINDING FUNCTIONS. HERE, FINA BIOSOLUTIONS (FINABIO) PROPOSES TO DEVELOP AND MANUFACTURE M8TT IN A PROPRIETARY ENGINEERED E. COLI STRAIN THAT HAS A UNIQUE OXIDATIVE ENVIRONMENT. THIS STRAIN HAS BEEN USED SUCCESSFULLY TO PRODUCE MULTI-GRAMS/L AMOUNTS OF CRM197, A MUTATED FORM OF DIPHTHERIA TOXIN THAT HAS BEEN SUCCESSFULLY USED AS A RECOMBINANTLY EXPRESSED VACCINE PROTEIN CARRIER. THIS PROPOSAL USES RECOMBINANT DNA TECHNOLOGY, BIOTECHNOLOGY, BIOCHEMISTRY AND IMMUNOLOGICAL APPROACHES TO PRODUCE AND TEST THE IMMUNOLOGICAL POTENCY OF THIS NEXT GENERATION CONJUGATE TETANUS VACCINE PLATFORM. THE SPECIFIC AIMS FOR PHASE I ARE TO: SUBCLONE AND SCALE UP PRODUCTION AND PURIFY > 1 G/L OF M8TT AT >95% PURITY; AND TO TEST THE IMMUNOLOGICAL PROPERTIES OF M8TT VERSUS CONVENTIONAL TTXD TO PRODUCE A CONJUGATE OF HEMOPHILUS INFLUENZAE SUBTYPE B POLYRIBITOL PHOSPHATE SUGAR PRP CONJUGATED TO M8TT AND TTXD TO DETERMINE IF PRP-TTXD IS A MORE POTENT CONJUGATE VACCINE TO PRP AND TT THAN PRP-TTXD. IF SUCCESSFUL, PHASE II STUDIES WILL OPTIMIZE THE M8TT MANUFACTURING PROCESS TO 50 L PRODUCTION SCALE AND CHARACTERIZE THE PRODUCT FOR SAFETY AND EFFICACY IN PRE-CLINICAL TRIALS. IN ADDITION, THE UTILITY OF M8TT AS A VACCINE CARRIER PROTEIN WILL BE FURTHER EXPLORED WITH ADDITIONAL ANTIGENS, INCLUDING SMALL MOLECULES AND OTHER POLYSACCHARIDES. ULTIMATELY, A SUPERIOR TETANUS VACCINE PROTEIN WILL BE COMMERCIALIZED BY ADVANCING A 50-YEAR OLD INDUSTRIAL TECHNOLOGY WITH A NEW, MODERNIZED, ECONOMIC, EFFECTIVE, AND SAFE CONJUGATE TT VACCINE PLATFORM.
$289.1k
1/11/22
Not listed
GENETICALLY DETOXIFIED TETANUS TOXIN FOR USE IN VACCINES - SUMMARY TETANUS AND DIPHTHERIA TOXOIDS ARE HIGHLY EFFECTIVE VACCINES FOR PREVENTING DISEASES. AS "CARRIER PROTEINS", TETANUS AND DIPHTHERIA TOXOIDS ENHANCE THE IMMUNOGENICITY OF SMALL MOLECULES AND POLYSACCHARIDES. HOWEVER, TETANUS TOXOID (TTXD) REPRESENTS ONLY 20-70% OF THE PROTEIN IN THE TTXD VACCINE AND THE TTXD VACCINE CONTAINS HUNDREDS OF 'UN-INTENDED/CONTAMINANT' CLOSTRIDIAL PROTEINS. PURIFICATION IS OFTEN NEEDED PRIOR TO TTXD USE A CONJUGATE VACCINE CARRIER. TT IS DETOXIFIED WITH FORMALDEHYDE, USING AN OVER 30-DAY INCUBATION THAT BLOCKS A SUBSET LYSINES THAT CANNOT THEN BE USED FOR CONJUGATION WITH ANTIGENS. COLLABORATORS AT THE MEDICAL COLLEGE OF WISCONSIN HAVE ENGINEERED A FULL-LENGTH, ATOXIC TETANUS TOXIN (M8TT) WITH 8 INDEPENDENT MUTATIONS REDUCING CATALYSIS, TRANSLOCATION, AND BINDING FUNCTIONS. HERE, FINA BIOSOLUTIONS (FINABIO) PROPOSES TO DEVELOP AND MANUFACTURE M8TT IN A PROPRIETARY ENGINEERED E. COLI STRAIN THAT HAS A UNIQUE OXIDATIVE ENVIRONMENT. THIS STRAIN HAS BEEN USED SUCCESSFULLY TO PRODUCE MULTI-GRAMS/L AMOUNTS OF CRM197, A MUTATED FORM OF DIPHTHERIA TOXIN THAT HAS BEEN SUCCESSFULLY USED AS A RECOMBINANTLY EXPRESSED VACCINE PROTEIN CARRIER. THIS PROPOSAL USES RECOMBINANT DNA TECHNOLOGY, BIOTECHNOLOGY, BIOCHEMISTRY AND IMMUNOLOGICAL APPROACHES TO PRODUCE AND TEST THE IMMUNOLOGICAL POTENCY OF THIS NEXT GENERATION CONJUGATE TETANUS VACCINE PLATFORM. THE SPECIFIC AIMS FOR PHASE I ARE TO: SUBCLONE AND SCALE UP PRODUCTION AND PURIFY > 1 G/L OF M8TT AT >95% PURITY; AND TO TEST THE IMMUNOLOGICAL PROPERTIES OF M8TT VERSUS CONVENTIONAL TTXD TO PRODUCE A CONJUGATE OF HEMOPHILUS INFLUENZAE SUBTYPE B POLYRIBITOL PHOSPHATE SUGAR PRP CONJUGATED TO M8TT AND TTXD TO DETERMINE IF PRP-TTXD IS A MORE POTENT CONJUGATE VACCINE TO PRP AND TT THAN PRP-TTXD. IF SUCCESSFUL, PHASE II STUDIES WILL OPTIMIZE THE M8TT MANUFACTURING PROCESS TO 50 L PRODUCTION SCALE AND CHARACTERIZE THE PRODUCT FOR SAFETY AND EFFICACY IN PRE-CLINICAL TRIALS. IN ADDITION, THE UTILITY OF M8TT AS A VACCINE CARRIER PROTEIN WILL BE FURTHER EXPLORED WITH ADDITIONAL ANTIGENS, INCLUDING SMALL MOLECULES AND OTHER POLYSACCHARIDES. ULTIMATELY, A SUPERIOR TETANUS VACCINE PROTEIN WILL BE COMMERCIALIZED BY ADVANCING A 50-YEAR OLD INDUSTRIAL TECHNOLOGY WITH A NEW, MODERNIZED, ECONOMIC, EFFECTIVE, AND SAFE CONJUGATE TT VACCINE PLATFORM.
$289.1k
1/11/22